Authors/Disclosures
|
Cathra Halabi, MD
(UCSF Department of Neurology)
|
The institution of Dr. Halabi has received research support from UC Noyce Initiative. The institution of Dr. Halabi has received research support from Weill Institute for Neurosciences Neurohub. The institution of Dr. Halabi has received research support from NIH/NIDCD. The institution of Dr. Halabi has received research support from NIH/StrokeNet. Dr. Halabi has a non-compensated relationship as a Working Group Member with National Academies of Sciences, Engineering, and Medicine Action Collaborative on TBI Care that is relevant to AAN interests or activities. Dr. Halabi has a non-compensated relationship as a Working Group Member with NIH/StrokeNet Recovery and Rehabilitation Working Group that is relevant to AAN interests or activities. |
|
Pei-Ning Wang, MD
|
Dr. Wang has nothing to disclose. |
|
Tamar Bacon
|
The institution of an immediate family member of Tamar Bacon has received research support from Novartis. The institution of an immediate family member of Tamar Bacon has received research support from Genentech. An immediate family member of Tamar Bacon has received publishing royalties from a publication relating to health care. |
|
|
No disclosure on file |
|
Anasheh Halabi, MD, PhD
(UCLA Department of Neurology)
|
Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Halabi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for PeerVoice. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas/Pfizer. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Halabi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia Therapeutics. The institution of Dr. Halabi has received research support from Pharnext. The institution of Dr. Halabi has received research support from AstraZeneca. |
|
Howard J. Rosen, MD
(UCSF)
|
Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |
|
Bruce L. Miller, MD, FAAN
(University of California, San Francisco)
|
Dr. Miller has nothing to disclose. |
|
Joel Kramer, PhD
(UCSF Medical Center)
|
The institution of Dr. Kramer has received research support from tau consortium. Dr. Kramer has received publishing royalties from a publication relating to health care. |
|
William W. Seeley, MD
|
Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Council. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Dr. Seeley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Seeley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lyterian Therapeutics. The institution of Dr. Seeley has received research support from NIH. The institution of Dr. Seeley has received research support from Rainwater Charitable Foundation. The institution of Dr. Seeley has received research support from Bluefield Project to Cure FTD. The institution of Dr. Seeley has received research support from Chan-Zuckerberg Initiative. |
|
|
No disclosure on file |